Articles - Page 64 of 96 - Drugs in Context

Motion sickness: an overview

Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Kam Lun Hon MD, FAAP, FCCM

Article Type

Review

Published

13 Dec 2019

This literature review provides an update on the current understanding of the pathophysiology and management of motion sickness.

Clinical potential of treatment with semaglutide in type 2 diabetes patients

Michael E Røder

Article Type

Review

Published

02 Dec 2019

This review discusses the efficacy and safety of semaglutide, which have
been investigated in an extensive clinical development
program including more than 9,000 patients with type 2
diabetes.

Drug therapy for double-hit lymphoma

Vania Phuoc MD, Jose Sandoval-Sus MD, Julio C Chavez MD, MS

Article Type

Review

Published

02 Dec 2019

This review discusses the role of hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy in DHL, as well as the role of potential novel agents such as BCL2 inhibitors, checkpoint inhibitors, bromodomain and extraterminal (BET) family inhibitors, Pi3K inhibitors, and others.

Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues

Ashutosh M Shukla MD, Aparna Wagle Shukla MD

Article Type

Review

Published

25 Nov 2019

This article reviews the expanding clinical applicability of chloroquine and related drugs includes rheumatological and cardiovascular disorders (CVD), chronic kidney disease (CKD), oncology, and a variety of nonmalarial infections.

Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature

Pietro Sollena MD, Maria Mannino MD, Francesco Tassone MD, Maria Alessandra Calegari MD, Ettore D’Argento MD, Ketty Peris MD

Article Type

Review

Published

06 Nov 2019

The authors tested the effectiveness of topical timolol 0.5% gel on paronychia and periungual pyogenic granuloma-like lesions being treated with EGFR-I and reviewed the available literature on this topic, which is the use of topical β-blockers in the management of EGFR-I-induced nail toxicities.